453 related articles for article (PubMed ID: 25030840)
1. Oral 9-cis retinoid for childhood blindness due to Leber congenital amaurosis caused by RPE65 or LRAT mutations: an open-label phase 1b trial.
Koenekoop RK; Sui R; Sallum J; van den Born LI; Ajlan R; Khan A; den Hollander AI; Cremers FP; Mendola JD; Bittner AK; Dagnelie G; Schuchard RA; Saperstein DA
Lancet; 2014 Oct; 384(9953):1513-20. PubMed ID: 25030840
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Amelioration of Cone Survival and Vision in a Mouse Model for Leber Congenital Amaurosis.
Li S; Samardzija M; Yang Z; Grimm C; Jin M
J Neurosci; 2016 May; 36(21):5808-19. PubMed ID: 27225770
[TBL] [Abstract][Full Text] [Related]
3. Safety and Proof-of-Concept Study of Oral QLT091001 in Retinitis Pigmentosa Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT).
Scholl HP; Moore AT; Koenekoop RK; Wen Y; Fishman GA; van den Born LI; Bittner A; Bowles K; Fletcher EC; Collison FT; Dagnelie G; Degli Eposti S; Michaelides M; Saperstein DA; Schuchard RA; Barnes C; Zein W; Zobor D; Birch DG; Mendola JD; Zrenner E;
PLoS One; 2015; 10(12):e0143846. PubMed ID: 26656277
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and rAAV gene therapy rescue of visual functions in a blind mouse model of Leber congenital amaurosis.
Batten ML; Imanishi Y; Tu DC; Doan T; Zhu L; Pang J; Glushakova L; Moise AR; Baehr W; Van Gelder RN; Hauswirth WW; Rieke F; Palczewski K
PLoS Med; 2005 Nov; 2(11):e333. PubMed ID: 16250670
[TBL] [Abstract][Full Text] [Related]
5. Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy.
Weleber RG; Pennesi ME; Wilson DJ; Kaushal S; Erker LR; Jensen L; McBride MT; Flotte TR; Humphries M; Calcedo R; Hauswirth WW; Chulay JD; Stout JT
Ophthalmology; 2016 Jul; 123(7):1606-20. PubMed ID: 27102010
[TBL] [Abstract][Full Text] [Related]
6. Intervisit variability of visual parameters in Leber congenital amaurosis caused by RPE65 mutations.
Roman AJ; Cideciyan AV; Schwartz SB; Olivares MB; Heon E; Jacobson SG
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1378-83. PubMed ID: 23341016
[TBL] [Abstract][Full Text] [Related]
7. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.
Bennett J; Wellman J; Marshall KA; McCague S; Ashtari M; DiStefano-Pappas J; Elci OU; Chung DC; Sun J; Wright JF; Cross DR; Aravand P; Cyckowski LL; Bennicelli JL; Mingozzi F; Auricchio A; Pierce EA; Ruggiero J; Leroy BP; Simonelli F; High KA; Maguire AM
Lancet; 2016 Aug; 388(10045):661-72. PubMed ID: 27375040
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.
Jacobson SG; Cideciyan AV; Ratnakaram R; Heon E; Schwartz SB; Roman AJ; Peden MC; Aleman TS; Boye SL; Sumaroka A; Conlon TJ; Calcedo R; Pang JJ; Erger KE; Olivares MB; Mullins CL; Swider M; Kaushal S; Feuer WJ; Iannaccone A; Fishman GA; Stone EM; Byrne BJ; Hauswirth WW
Arch Ophthalmol; 2012 Jan; 130(1):9-24. PubMed ID: 21911650
[TBL] [Abstract][Full Text] [Related]
9. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.
Maguire AM; High KA; Auricchio A; Wright JF; Pierce EA; Testa F; Mingozzi F; Bennicelli JL; Ying GS; Rossi S; Fulton A; Marshall KA; Banfi S; Chung DC; Morgan JI; Hauck B; Zelenaia O; Zhu X; Raffini L; Coppieters F; De Baere E; Shindler KS; Volpe NJ; Surace EM; Acerra C; Lyubarsky A; Redmond TM; Stone E; Sun J; McDonnell JW; Leroy BP; Simonelli F; Bennett J
Lancet; 2009 Nov; 374(9701):1597-605. PubMed ID: 19854499
[TBL] [Abstract][Full Text] [Related]
10. Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy.
Pennesi ME; Weleber RG; Yang P; Whitebirch C; Thean B; Flotte TR; Humphries M; Chegarnov E; Beasley KN; Stout JT; Chulay JD
Hum Gene Ther; 2018 Dec; 29(12):1428-1437. PubMed ID: 29869534
[TBL] [Abstract][Full Text] [Related]
11. The phenotype of Severe Early Childhood Onset Retinal Dystrophy (SECORD) from mutation of RPE65 and differentiation from Leber congenital amaurosis.
Weleber RG; Michaelides M; Trzupek KM; Stover NB; Stone EM
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):292-302. PubMed ID: 20811047
[TBL] [Abstract][Full Text] [Related]
12. Nature of the visual loss in observers with Leber's congenital amaurosis caused by specific mutations in RPE65.
Ripamonti C; Henning GB; Ali RR; Bainbridge JW; Robbie SJ; Sundaram V; Luong VA; van den Born LI; Casteels I; de Ravel TJ; Moore AT; Stockman A
Invest Ophthalmol Vis Sci; 2014 Sep; 55(10):6817-28. PubMed ID: 25257057
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal and cross-sectional study of patients with early-onset severe retinal dystrophy associated with RPE65 mutations.
Paunescu K; Wabbels B; Preising MN; Lorenz B
Graefes Arch Clin Exp Ophthalmol; 2005 May; 243(5):417-26. PubMed ID: 15565294
[TBL] [Abstract][Full Text] [Related]
14. Cone-rod dystrophy caused by a novel homozygous RPE65 mutation in Leber congenital amaurosis.
Jakobsson C; Othman IS; Munier FL; Schorderet DF; Abouzeid H
Klin Monbl Augenheilkd; 2014 Apr; 231(4):405-10. PubMed ID: 24771178
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 9-cis-retinyl acetate therapy in Rpe65-/- mice.
Maeda T; Maeda A; Casadesus G; Palczewski K; Margaron P
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4368-78. PubMed ID: 19407008
[TBL] [Abstract][Full Text] [Related]
16. Early onset retinal dystrophy due to mutations in LRAT: molecular analysis and detailed phenotypic study.
Dev Borman A; Ocaka LA; Mackay DS; Ripamonti C; Henderson RH; Moradi P; Hall G; Black GC; Robson AG; Holder GE; Webster AR; Fitzke F; Stockman A; Moore AT
Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):3927-38. PubMed ID: 22570351
[TBL] [Abstract][Full Text] [Related]
17. Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis.
Deng C; Zhao PY; Branham K; Schlegel D; Fahim AT; Jayasundera TK; Khan N; Besirli CG
Graefes Arch Clin Exp Ophthalmol; 2022 May; 260(5):1543-1550. PubMed ID: 35001204
[TBL] [Abstract][Full Text] [Related]
18. [Gene therapy for vision restoration in patients with Leber congenital amaurosis (LCA) due to RPE65 gene mutations: beginning the phase IV trial].
Chacón-Camacho ÓF; Zenteno JC
Gac Med Mex; 2017; 153(2):276-278. PubMed ID: 28474714
[TBL] [Abstract][Full Text] [Related]
19. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.
Le Meur G; Lebranchu P; Billaud F; Adjali O; Schmitt S; Bézieau S; Péréon Y; Valabregue R; Ivan C; Darmon C; Moullier P; Rolling F; Weber M
Mol Ther; 2018 Jan; 26(1):256-268. PubMed ID: 29033008
[TBL] [Abstract][Full Text] [Related]
20. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement.
Cideciyan AV; Jacobson SG; Beltran WA; Sumaroka A; Swider M; Iwabe S; Roman AJ; Olivares MB; Schwartz SB; Komáromy AM; Hauswirth WW; Aguirre GD
Proc Natl Acad Sci U S A; 2013 Feb; 110(6):E517-25. PubMed ID: 23341635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
